牛磺鹅去氧胆酸
牛磺鹅去氧胆酸 性质
| 熔点 | 186-200°C |
|---|---|
| 密度 | 1.216±0.06 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 可溶于氯仿、甲醇 |
| 形态 | 固体 |
| 酸度系数(pKa) | 1.42±0.50(Predicted) |
| 颜色 | 白色至浅棕色 |
| InChIKey | BHTRKEVKTKCXOH-ZNKJZDQHNA-N |
| SMILES | [C@@]12([H])CC[C@H]([C@H](C)CCC(=O)NCCS(=O)(=O)O)[C@@]1(C)CC[C@]1([H])[C@@]3(C)CC[C@@H](O)C[C@@]3([H])C[C@@H](O)[C@@]21[H] |&1:0,4,5,18,22,24,28,31,34,36,r| |
牛磺鹅去氧胆酸 用途与合成方法
|
Human Endogenous Metabolite
|
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities.
Taurochenodeoxycholic acid (12-Deoxycholyltaurine; 0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2.
Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation.
Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats.
牛磺鹅去氧胆酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-N2027 | 牛磺鹅去氧胆酸 | 516-35-8 | 25 mg | 400 |
| 2025-12-22 | HY-N2027 | 牛磺鹅去氧胆酸 | 516-35-8 | 10mM * 1mLin DMSO | 440 |
